奥美拉唑联合奥曲肽治疗肝硬化上消化道出血的效果及安全性分析

Analysis of effect and safety by omeprazole combined with octreotide in the treatment of liver cirrhosis and upper gastrointestinal hemorrhage

目的探讨奥美拉唑联合奥曲肽治疗肝硬化上消化道出血的临床疗效与安全性。方法 102例肝硬化上消化道出血患者作为此次研究对象,随机将患者分成对照组与治疗组,每组51例。对照组单用奥美拉唑治疗,治疗组应用奥美拉唑联合奥曲肽治疗,比较两组患者的临床疗效与安全性。结果治疗组患者的平均止血时间、输血量以及住院时间均显著少于对照组(P<0.05);治疗组治疗总有效率为94.12%,不良反应发生率为5.88%,均优于对照组的68.63%、33.33%,差异具有统计学意义(P<0.05)。结论肝硬化上消化道出血应用奥美拉唑联合奥曲肽治疗能够获得显著临床疗效,可显著减少患者出血量,安全性高,值得临床推广。

Objective To investigate clinical effect and safety by omeprazole combined with octreotide in the treatment of liver cirrhosis and upper gastrointestinal hemorrhage. Methods A total of 102 patients with liver cirrhosis and upper gastrointestinal hemorrhage as study subjects were randomly divided into control group and treatment group, with 51 cases in each group. The control group received omeprazole alone for treatment, and the treatment group received omeprazole combined with octreotide for treatment. Comparison was made on clinical effect and safety between the two groups. Results The treatment group had all less mean hemostasis time, blood transfusion volume and hospital stay time than the control group（P〈0.05）. The treatment group had total effective rate in treatment as 94.12% and incidence of adverse reactions as 5.88%, which were all better than 68.63% and 33.33% in the control group, and their difference had statistical significance（P〈0.05）. Conclusion Implement of omeprazole combined with octreotide shows excellent clinical effect in the treatment of liver cirrhosis and upper gastrointestinal hemorrhage. This method can remarkably reduce bleeding volume with high safety, and it is worth clinical promotion.